On Oct 23, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $179.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Mizuho Securities analyst Ann Hynes maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The integration of LifeLabs and consistent elevated utilization trends are the main factors behind the updated guidance for Quest Diagnostics. The company's defensive characteristics, especially during an election cycle, and more secure estimates for future years remain positive aspects highlighted by analysts.
Quest Diagnostics delivered a strong performance in the third quarter, exceeding expectations. The company maintained its earnings forecast even in the face of challenges posed by hurricanes. Additionally, preliminary insights regarding the fiscal year 2025 appear promising.
The laboratory sector is viewed favorably for the year 2025, with the belief that it is unnecessary to shy away from an investment due to cost considerations when compared to alternatives. Quest Diagnostics is seen as having a series of drivers that will contribute to expedited growth in 2025. Notably, the company's growth is expected to continue due to the completion of eight acquisitions in the preceding year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
